Lexeo Therapeutics, Inc. Common Stock

LXEONASDAQ • USD
ThemeGenomics & Precision Med.›Gene Therapy & Gene Editing
4.15 USD
↘ 0.08 (1.90%)🔴AT CLOSE (AS OF 07:31 PM EDT)
🔴Market: CLOSED

Lexeo Therapeutics, Inc. Common Stock (LXEO) trades at $4.15 per share. Our models show a "Strong Sell" technical signal alongside a "Neutral" fundamental rating. This is driven by a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. Valuation metrics suggest LXEO is trading at a discount to its peers, earning an "Attractively Valued" rating.

Technical & fundamental data as of Sep 15, 2026.

Open?$4.18
High?$4.28
Low?$4.01
Prev. Close?$4.21
Volume?888.4K
Avg. Volume?819.7K
VWAP?$4.16
Rel. Volume?1.08x
Bid / Ask
Bid?$4.01 × 300
Ask?$4.99 × 100
Spread?$0.98
Midpoint?$4.50
Valuation & Ratios
Market Cap?338.9M
Shares Out?82.0M
Float?73.2M
Float %?93.2%
P/E Ratio?N/A
P/B Ratio?1.44
EPS?-$1.06
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.
Themes
Healthcare - Genomics & Precision Medicine›Gene Therapy & Gene EditingBiotech - Drug Development›Rare Disease Therapeutics
Employees
59
Market Cap
345.4M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
www.lexeotx.com
Listed
2023-11-03
Address
345 PARK AVENUE SOUTH
NEW YORK, NY 10010
Phone: (212) 547-9879
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-3/3)
Medium-Term (Wave)?▼ Bearish(-3/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
100
Momentum?
77
Short Sent.?
30
Piotroski F-Score?0/9Weak
Altman Z-Score?7.83Safe
Confidence?48%Low
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?28.00%Squeeze Risk
Short Interest?20.5M
Days to Cover?26.8
Free Float73.2M
Avg Daily Volume763.9K
Settlement Date2026-08-31
Financial Health
Current Ratio?13.89Strong
Quick Ratio?13.89Strong
Cash Ratio?5.92Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
100/100
P/E?
N/A▾
P/B?
Peers
100
S&P
88
1.44CHEAP▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-2.6CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
3
-37.1%WEAK▾
ROA?
S&P
3
-34.2%WEAK▾
Cash Flow & Enterprise
FCF?$-88698000
Enterprise Value?$246.6M
Fundamentals ratios updated end of day
MarketsMoversWatchlist